Patient-reported impact of symptoms in myotonic dystrophy type 1 (PRISM-1)
about
Patient-identified disease burden in facioscapulohumeral muscular dystrophy.Patient-Reported Impact of Symptoms in Myotonic Dystrophy Type 2 (PRISM-2).Myotonic Dystrophies: State of the Art of New Therapeutic Developments for the CNS.The UK Myotonic Dystrophy Patient Registry: facilitating and accelerating clinical researchHard ways towards adulthood: the transition phase in young people with myotonic dystrophy.Diagnostic odyssey of patients with myotonic dystrophyQuality-of-life in Charcot-Marie-Tooth disease: the patient's perspective.The relationship between physical symptoms and health-related quality of life in oculopharyngeal muscular dystrophy.Parent-reported multi-national study of the impact of congenital and childhood onset myotonic dystrophy.Multidimensional aspects of pain in myotonic dystrophies.Patient identification of the symptomatic impact of charcot-marie-tooth disease type 1A.Myotonic dystrophy health index: Correlations with clinical tests and patient functionThe Impact of Pregnancy on Myotonic Dystrophy: A Registry-Based StudyThe Mef2 transcription network is disrupted in myotonic dystrophy heart tissue, dramatically altering miRNA and mRNA expression.Daytime sleepiness and myotonic dystrophy.Activity rating scales in adult muscle disease: what do they actually measure?Sleep-Wake Cycle and Daytime Sleepiness in the Myotonic DystrophiesEvolving Motivations: Patients' and Caregivers' Perceptions About Seeking Myotonic Dystrophy (DM1) and Huntington's Disease Care.Survey of Canadian Myotonic Dystrophy Patients' Access to Computer Technology.Major involvement of trunk muscles in myotonic dystrophy type 1.Medication adherence in patients with myotonic dystrophy and facioscapulohumeral muscular dystrophy.Quantitative Assessment of Trunk Muscles Involvement in Patients with Myotonic Dystrophy Type 1 Using a Whole Body Muscle Magnetic Resonance Imaging.Myotonic Dystrophy Type 1 Management and Therapeutics.Review of patient-reported outcome measures for use in myotonic dystrophy type 1 patients.Myotonic Dystrophy and Huntington's Disease Care: "We Like to Think We're Making a Difference".Variability of multisystemic features in myotonic dystrophy type 1--lessons from Serbian registry.Pain location and intensity impacts function in persons with myotonic dystrophy type 1 and facioscapulohumeral dystrophy with chronic pain.Myotonic Dystrophy Health Index: initial evaluation of a disease-specific outcome measure.Patient-identified impact of symptoms in spinal and bulbar muscular atrophy.Truths and misinformation: a qualitative exploration of myotonic dystrophy.The impact of congenital and childhood myotonic dystrophy on quality of life: a qualitative study of associated symptoms.French translation and cross-cultural adaptation of The Myotonic Dystrophy Health Index.Orexin/hypocretin levels in the cerebrospinal fluid and characteristics of patients with myotonic dystrophy type 1 with excessive daytime sleepiness.Increased EEG Theta Spectral Power in Sleep in Myotonic Dystrophy Type 1.Outcome Measures for Central Nervous System Evaluation in Myotonic Dystrophy Type 1 May Be Confounded by Deficits in Motor Function or Insight
P2860
Q30583657-6EBAC870-9F10-48AC-ABC6-1813F78AFA8BQ30692540-3CF63894-0B3C-4EF6-A299-BF8E00BE6E9BQ33580885-6AA87A81-5BDB-4AE1-B2F7-92879EC4AD3EQ33627845-50D77405-A1AD-467E-8465-4E364D6AEBBDQ33635770-50F73ECE-F046-49F9-B39B-8F07768B88B7Q34172180-9E8E0BB7-8907-4FA1-A434-C974B090E9E2Q34621607-340BC9B4-8E57-4DB5-BE6E-17F17C11105EQ36783791-C2A3C1C5-733A-4A71-91C6-AFE975F680EEQ36844836-6F3CD5D5-8D4D-4F50-9656-05FAD5CDFD39Q36876599-76DB5520-881B-4E2C-8542-9B51477F2820Q37119243-264C47F1-619A-496B-950B-108567885FADQ37165392-89EEAD24-1F76-4081-B1AE-480C34EA6CFBQ37589784-E0C791B3-1345-4169-8726-A53600F1F984Q37590150-A5BD6B7B-AB00-4689-9098-748371974391Q38083615-7C89909B-8E4C-4AA7-A6F6-883B10C57508Q38152335-3B3A2228-D7EC-4C5C-A3B5-CA119D9B1275Q38575770-B9D9C90E-9C2B-4A11-B22E-E9348DB1D513Q38629175-FA2CF5EB-AA2A-450A-BEC8-FE7D207E2ADFQ38768565-583B4EE1-1090-40CA-8D3A-2798453CC394Q38809790-0F1B1185-ECB3-4C2B-A80B-83EE8F7A1071Q38812196-B52CA2AE-B025-4832-9C37-5A207BABCD88Q38910890-0DF1DEB7-824A-491F-9345-38234124EB03Q39003493-C6D7535A-61E0-4C42-AFA6-84FD358369A8Q39012912-C4460681-812D-44F2-945D-D01F09EEDBCAQ39349990-B23C2659-BAB1-40BB-88D7-B922B3518951Q40726509-EDFC8588-48BA-4942-863E-E94FEDD2BC1AQ41205792-5A8C7CB6-105F-4C02-9E13-AF031356FA60Q41345571-E397FDC7-3EF3-47BF-B0E1-D9CC2A8D47CFQ47298620-A68DCE92-2937-4D22-A5FA-2B67FEF3A229Q47717264-50E20115-C75D-4640-9644-9A67674F5FE3Q48256312-62B18AF8-0EED-493E-85D9-1C4409A93159Q48570241-C2B94B57-8948-4445-8EE6-8CF7B9A2AF0BQ49502636-3394EB5A-E259-417C-8160-7FD9032A5F47Q50210167-A06DC286-F799-4BEC-817B-CFE3CD107472Q58586761-C4EBFE06-D33B-4AB3-92B8-0A33957BF3EA
P2860
Patient-reported impact of symptoms in myotonic dystrophy type 1 (PRISM-1)
description
2012 nî lūn-bûn
@nan
2012 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Patient-reported impact of symptoms in myotonic dystrophy type 1 (PRISM-1)
@ast
Patient-reported impact of symptoms in myotonic dystrophy type 1 (PRISM-1)
@en
type
label
Patient-reported impact of symptoms in myotonic dystrophy type 1 (PRISM-1)
@ast
Patient-reported impact of symptoms in myotonic dystrophy type 1 (PRISM-1)
@en
prefLabel
Patient-reported impact of symptoms in myotonic dystrophy type 1 (PRISM-1)
@ast
Patient-reported impact of symptoms in myotonic dystrophy type 1 (PRISM-1)
@en
P2093
P2860
P1433
P1476
Patient-reported impact of symptoms in myotonic dystrophy type 1 (PRISM-1)
@en
P2093
Barbara Vickrey
Chad Heatwole
Charles Thornton
Christine Quinn
David Victorson
Michael P McDermott
Nan Rothrock
Nicholas Johnson
Richard Moxley
P2860
P304
P356
10.1212/WNL.0B013E318260CBE6
P407
P577
2012-07-11T00:00:00Z